| Literature DB >> 30464867 |
Shiori Tomita1, Daiki Kobayashi1, Kuniyoshi Hayashi2, Hiroko Arioka1.
Abstract
BACKGROUND: Polypharmacy is associated with negative outcomes in older population. Managing polypharmacy is important but there is no definite method for regulating it. Our aim was to evaluate what medications and patient's background are associated with reducing polypharmacy.Entities:
Keywords: acute care hospital; drug/medical use evaluation; geriatrics; physician prescribing; polypharmacy
Year: 2018 PMID: 30464867 PMCID: PMC6238230 DOI: 10.1002/jgf2.207
Source DB: PubMed Journal: J Gen Fam Med ISSN: 2189-7948
Baseline characteristics (n = 494)
| Age | |||
| Mean ± SD | 79.6 ± 7.8 | ||
| Sex n (%) | |||
| Male | 247 (50.0) | ||
| The number of medications | Admission | Discharge | |
| Mean ± SD | 6.9 ± 4.7 | 6.8 ± 4.3 | |
| Median (range) | 7 (0‐26) | 7 (0‐23) | |
| The number of medications on admission by age | |||
| <75 (n = 144) | 75‐85 (n = 200) | ≧85 (n = 150) | |
| 0‐4 n (%) | 68 (47.2) | 54 (27.0) | 41 (27.3) |
| 5‐9 n (%) | 50 (34.7) | 85 (42.5) | 68 (45.3) |
| 10‐14 n (%) | 20 (13.8) | 49 (24.5) | 29 (19.3) |
| Over 15 n (%) | 6 (4.2) | 12 (6.0) | 12 (8.0) |
| Living place before admission | |||
| Home, n (%) | 429 (86.8) | ||
| Hospital, n (%) | 2 (0.4) | ||
| Care home, n (%) | 47 (9.5) | ||
| Unknown, n (%) | 16 (3.2) | ||
Paired t tests of the numbers of prescribed medications upon admission and at discharge
| ATC classification | The mean number of medications prescribed upon admission | The mean number of medications prescribed at discharge |
| Pre‐ and postratio |
|---|---|---|---|---|
| A02 drugs for acid‐related disorders | 0.76 | 0.85 | 0.1 | 1.12 |
| A03 drugs for functional gastrointestinal disorders | 0.11 | 0.04 | <0.01 | 0.36 |
| A05 bile and liver therapy | 0.27 | 0.19 | <0.05 | 0.70 |
| A06 drugs for constipation | 0.18 | 0.17 | 0.62 | 0.94 |
| A07 antidiarrheals, intestinal, anti‐inflammatory/antiinfective agents | 0.02 | 0.01 | 0.25 | 0.50 |
| A09 digestives, incl. enzymes | 0.29 | 0.25 | 0.3 | 0.86 |
| A10 drugs used in diabetes | 0.19 | 0.17 | 0.47 | 0.89 |
| A11 vitamins | 0.03 | 0.12 | <0.01 | 4.00 |
| A12 mineral, supplements | 0.02 | 0.02 | 0.56 | 1.00 |
| A16 other alimentary tract and metabolism products | 0.02 | 0.02 | 0.56 | 1.00 |
| B01 antithrombotic agents | 0.52 | 0.55 | 0.47 | 1.06 |
| B02 antihemorrhagics | 0.04 | 0.04 | 0.74 | 1.00 |
| B03 antianemic preparations | 0.16 | 0.14 | 0.46 | 0.88 |
| C01 cardiac therapy | 0.2 | 0.2 | 1 | 1.00 |
| C02 antihypertensives | 0.06 | 0.06 | 0.9 | 1.00 |
| C03 diuretics | 0.34 | 0.27 | 0.11 | 0.79 |
| C04 peripheral vasodilators | 0.03 | 0.01 | <0.05 | 0.33 |
| C07 beta‐blocking agents | 0.2 | 0.24 | 0.23 | 1.20 |
| C08 calcium channel blockers | 0.38 | 0.35 | 0.44 | 0.92 |
| C09 agents acting on the renin‐angiotensin system | 0.41 | 0.28 | <0.01 | 0.68 |
| C10 lipid modifying agents | 0.31 | 0.28 | 0.25 | 0.90 |
| D01 antifungals for dermatological use | 0.03 | 0.03 | 0.84 | 1.00 |
| G04 urologicals | 0.15 | 0.14 | 0.55 | 0.93 |
| H02 corticosteroids for systemic use | 0.11 | 0.13 | 0.39 | 1.18 |
| H03 thyroid therapy | 0.08 | 0.11 | 0.16 | 1.38 |
| J01 antibacterials for systemic use | 0.07 | 0.25 | <0.01 | 3.57 |
| J02 antimycotics for systemic use | 0.01 | 0.04 | <0.01 | 4.00 |
| J04 antimycobacterials | 0 | 0.02 | <0.05 | NA |
| L01 antineoplastic agents | 0.03 | 0.01 | 0.09 | 0.33 |
| L02 endocrine therapy | 0.03 | 0.03 | 1 | 1.00 |
| L04 immunosuppressants | 0.04 | 0.03 | 0.33 | 0.75 |
| M01 anti‐inflammatory and antirheumatic products | 0.06 | 0.05 | 0.49 | 0.83 |
| M02 topical products for joint and muscular pain | 0.03 | 0.03 | 0.84 | 1.00 |
| M03 muscle relaxants | 0.02 | 0.02 | 0.78 | 1.00 |
| M04 antigout preparations | 0.14 | 0.1 | 0.11 | 0.71 |
| N02 analgesics | 0.1 | 0.13 | 0.1 | 1.30 |
| N03 antiepileptics | 0.11 | 0.12 | 0.81 | 1.09 |
| N04 anti‐Parkinson drugs | 0.1 | 0.06 | 0.09 | 0.60 |
| N05 psycholeptics | 0.47 | 0.5 | 0.6 | 1.06 |
| N06 psychoanaleptics | 0.16 | 0.26 | <0.01 | 1.63 |
| N07 other nervous system drugs | 0.02 | 0.02 | 0.28 | 1.00 |
| R03 drugs for obstructive airway diseases | 0.03 | 0.13 | <0.01 | 4.33 |
| R05 cough and cold preparations | 0.12 | 0.18 | <0.01 | 1.50 |
| R06 antihistamines for systemic use | 0.07 | 0.05 | 0.16 | 0.71 |
| Chinese medicine | 0.09 | 0.06 | 0.12 | 0.67 |
ATC, anatomical therapeutic chemical.
Logistic regression analyses of association between variables and reduction of medications
| Variable | Odds ratio | 95% CI |
|
|---|---|---|---|
| Age (y.o) <75 | Reference | ||
| 75‐85 | 1.0 | 0.91‐1.12 | 0.80 |
| ≧85 | 1.02 | 0.91‐1.16 | 0.66 |
| BMI(kg/m2) <18.5 | 0.94 | 0.84‐1.04 | 0.20 |
| 18.5‐25 | Reference | ||
| ≧25 | 0.96 | 0.85‐1.13 | 0.80 |
| Sex female | 1.07 | 0.97‐1.16 | 0.16 |
| Length of hospital stay categorical | 0.99 | 0.99‐1.0 | <0.01 |
| The number of medication on admission | 1.05 | 1.04‐1.06 | <0.01 |
| Living space on admission | Reference | ||
| Home | |||
| Hospital | 0.5 | 0.2‐1.15 | 0.10 |
| Care home | 0.99 | 0.83‐1.16 | 0.80 |
BMI, body mass index; CI, confidence interval.